Quarterly report pursuant to Section 13 or 15(d)

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (unaudited)

v3.20.1
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (unaudited) - USD ($)
$ in Thousands
3 Months Ended
Mar. 31, 2020
Mar. 31, 2019
COSTS AND EXPENSES:    
Research and development $ 4,676 $ 3,896
General and administrative 2,621 2,401
Total costs and expenses 7,297 6,297
Operating Loss (7,297) (6,297)
Interest income, net 24 64
Net loss (7,273) (6,233)
Warrant deemed dividend 451  
Preferred stock deemed dividend 1,260  
Net loss available to common stockholders $ (8,984) $ (6,233)
Net loss per common share, basic and diluted (in dollars per share) $ (0.37) $ (12.76)
Weighted average common shares outstanding, basic and diluted (in shares) 24,028,970 488,315